Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.

about

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema

P2860

Q49275652-1F373405-0A11-480D-8D29-9B00DBC22914 Q58792817-0E74B08F-9048-4F8F-ADAF-388F95022859

P2860

Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.

Item

http://www.wikidata.org/entity/Q39292954

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@en

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@nl

type

Item

label

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@en

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@nl

prefLabel

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@en

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@nl

P1476

Ranibizumab in the Treatment o ...... eeds, and Emerging Challenges.

@en

P2093

Athanasia Maria Mikropoulou

http://www.w3.org/2001/XMLSchema#string

Nikolaos Dervenis

http://www.w3.org/2001/XMLSchema#string

Panagiotis Dervenis

http://www.w3.org/2001/XMLSchema#string

Paris Tranos

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

Tumor angiogenesis: therapeutic implications

The biology of VEGF and its receptors

The Mesobuthus martensii genome reveals the molecular diversity of scorpion toxins

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

P2888

s12325-017-0548-1

P304

1270-1282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12325-017-0548-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28484955

http://www.w3.org/2001/XMLSchema#string

P921

peptide

macular retinal edema

P932

5487872

http://www.w3.org/2001/XMLSchema#string

Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.

about

P2860

P2860

Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932